DrugPatentWatch Database Preview
Cipla Company Profile
» See Plans and Pricing
What is the competitive landscape for CIPLA, and when can generic versions of CIPLA drugs launch?
CIPLA has eighty-nine approved drugs.
There are four US patents protecting CIPLA drugs. There are thirty-one tentative approvals on CIPLA drugs.
There are twenty-three patent family members on CIPLA drugs in twenty-one countries and three hundred and sixty-three supplementary protection certificates in seventeen countries.
Summary for Cipla
| International Patents: | 23 |
| US Patents: | 4 |
| Tradenames: | 79 |
| Ingredients: | 79 |
| NDAs: | 89 |
| Patent Litigation for Cipla: | See patent lawsuits for Cipla |
| PTAB Cases with Cipla as petitioner: | See PTAB cases with Cipla as petitioner |
Drugs and US Patents for Cipla
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cipla | PRAVASTATIN SODIUM | pravastatin sodium | TABLET;ORAL | 077904-002 | Oct 23, 2006 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Cipla | LAMIVUDINE AND ZIDOVUDINE | lamivudine; zidovudine | TABLET;ORAL | 077411-001 | Sep 7, 2018 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Cipla | TADALAFIL | tadalafil | TABLET;ORAL | 209539-001 | Mar 26, 2019 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Cipla | FLUTAMIDE | flutamide | CAPSULE;ORAL | 075780-001 | Sep 19, 2001 | AB | RX | No | Yes | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cipla Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Spain | 2613936 | Start Trial |
| Canada | 2706369 | Start Trial |
| Lithuania | 2217610 | Start Trial |
| Taiwan | 200927146 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cipla Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0740668 | PA2003001,C0740668 | Lithuania | Start Trial | PRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328 |
| 0900210 | 05C0030 | France | Start Trial | PRODUCT NAME: ATAZANAVIR ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/03/267/001 DU 20040302; REGISTRATION NO/DATE AT EEC: EU/1/03/237/001 DU 20040302 |
| 2487163 | 93353 | Luxembourg | Start Trial | PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI ET ATAZANAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE SULFATE D'ATAZANAVIR; AUTHORISATION NUMBER AND DATE: EU/1/15/1025 |
| 1507558 | 12C0033 | France | Start Trial | PRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: 6167801 20110705 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
